Inhibition of CYP3A by erythromycin: In vitro-in vivo correlation in rats

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 61-72

  Zhang, Xin ^a,e   Galinsky, Raymond E ^b,d   Kimura, Robert E ^c   Quinney, Sara K ^d   Jones, David R ^d   Hall, Stephen D ^d  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A2; ERYTHROMYCIN; MESSENGER RNA; MIDAZOLAM;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CANNULATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; HALF LIFE TIME; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ALGORITHMS; ANIMALS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; GENE EXPRESSION; KINETICS; LIVER; MALE; MEMBRANE PROTEINS; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 73149102530     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028290     Document Type: Article

References (40)

1. Amacher DE, Schomaker SJ, and Retsema JA (1991) Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 35:1186-1190.
2. Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, and Hall SD (2002) The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 53:67-74.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
4. Chien JY, Thummel KE, and Slattery JT (1997) Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 25:1165-1175.
5. Clarke SE and Jeffrey P (2001) Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31:591-598.
6. Correia MA (1991) Cytochrome P450 turnover. Methods Enzymol 206:315-325.
7. Danan G, Descatoire V, and Pessayre D (1981) Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 218:509-514.
8. Franke RM, Baker SD, Mathijssen RH, Schuetz EG, and Sparreboom A (2008) Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 84:704-709.
9. Franklin MR (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559-573.
10. Franklin MR and Estabrook RW (1971) On the inhibitory action of mersalyl on microsomal drug oxidation: a rigid organization of the electron transport chain. Arch Biochem Biophys 143: 318-329.
11. Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
12. Lam JL, Okochi H, Huang Y, and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos 34:1336-1344.
13. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, and Pessayre D (1983) Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 32:1063-1068.
14. Lindstrom T, Hanssen B, and Wrighton S (1993) Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrobial Agents Chemother 37:265-269.
15. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
16. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
17. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
18. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
19. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
20. Omura T and Sato R (1962) A new cytochrome in liver microsomes. J Biol Chem 237:1375-1376.
21. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
22. Pershing LK and Franklin MR (1982) Cytochrome P-450 metabolic- intermediate complex formation and induction by macrolide antibiotics; a new class of agents. Xenobiotica 12:687-699.
23. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, and Kimura RE (2008) Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos 36:1097-1101.
24. Ronis MJ, Chen Y, Badeaux J, Llaurenzana E, and Badger T (2006) Soy protein isolate induces CYP3A1 and CYP3A2 in prepubertal rats. Exp Biol Med (Maywood) 231:60-69.
25. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
26. Schwenk M (1988) Mucosal biotransformation. Toxicol Pathol 16:138-146.
27. Shaw AA, Hall SD, Franklin MR, and Galinsky RE (2002) The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos 30:177-182.
28. Shiraki H and Guengerich FP (1984) Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase. Arch Biochem Biophys 235:86-96.
29. Takedomi S, Matsuo H, Yamano K, Ohtani H, and Sawada Y (2001) In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J Pharm Pharmacol 53:643-651.
30. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
31. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
32. Uhing MR, Beno DW, Jiyamapa-Serna VA, Chen Y, Galinsky RE, Hall SD, and Kimura RE (2004) The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metab Dispos 32:1325-1330.
33. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
34. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
35. Watkins PB, Wrighton SA, Schuetz EG, Maurel P, and Guzelian PS (1986) Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 261:6264-6271.
36. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.
37. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, and Iga T (2000) Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118-1126.
38. Zhang X, Jones DR, and Hall SD (2008) Mechanism-based inhibition of human cytochromes P450: in vitro kinetics and in vitro-in vivo correlations, in Drug-Drug Interactions, 2nd ed (Rodrigues AS ed) Marcel Dekker, New York, NY.
39. Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597.
40. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, and Xu A (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415-442.